Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ME3 | Q16798 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6615592 | 0.93 | HPGD (0.63) | GAAMEN1KMT2AMAPTGFER | |
| SCHEMBL3814690 | 0.93 | HPGD (0.58) | GAAMEN1KMT2AMAPTGFER | |
| SCHEMBL693444 | 0.92 | HPGD (0.66) | GAAHPGDLMNASMN1; SMN2NPSR1 | |
| SCHEMBL2386265 | 0.89 | SIRT2 (0.48) | GAAMEN1KMT2AMAPTGFER | |
| SCHEMBL6756210 | 0.82 | HPGD (0.45) | GAAMEN1KMT2AHPGDNPC1 | |
| SCHEMBL6757892 | 0.82 | HPGD (0.49) | GAAMEN1KMT2AHPGDLMNA | |
| SCHEMBL6282431 | 0.81 | HPGD (0.51) | GAAHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL2445063 | 0.80 | PTPN2 (0.68) | KMT2ANAMPTNPC1RAB9A | |
| SCHEMBL883845 | 0.78 | NAMPT (0.61) | GAAMEN1KMT2AMAPTGFER | |
| SCHEMBL10826501 | 0.78 | ACKR3 (0.41) | GAAMEN1KMT2AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-06-29 | — | — | US | claimed |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-05-13 | — | — | US | claimed |
| US-10729681-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2020-08-04 | — | — | US | claimed |
| US-20190192494-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2019-06-27 | — | — | US | claimed |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | claimed |
| EP-2892892-B1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-31 | — | — | EP | claimed |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | claimed |
| EP-2892892-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR!THE TREATMENT OF CANCER | Janssen Pharmaceutica N.V. (BE) | 2015-07-15 | — | — | EP | claimed |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, NV (BE) | 2015-04-09 | — | — | US | claimed |
| WO-2014039769-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR|THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-13 | — | — | WO | claimed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | claimed |
| EP-1635824-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | Novartis AG (CH) | 2006-03-22 | — | — | EP | claimed |
| WO-2005000298-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | claimed |
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | claimed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | claimed |
| CN-1343206-A | Cyclocompound | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-04-03 | — | — | CN | claimed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | claimed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | claimed |
| US-11883386-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-06-29 | — | — | US | disclosed |
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3357911-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-10729681-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| US-20190192494-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2019-06-27 | — | — | US | disclosed |
| US-RE47437-E1 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180327401-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-15 | — | — | US | disclosed |
| EP-3026044-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS INC (US) | 2018-11-07 | — | — | EP | disclosed |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | disclosed |
| EP-3357911-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3323807-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20170189387-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT COMPANY, LLC (PR) | 2017-07-06 | — | — | US | disclosed |
| EP-2892892-B1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-31 | — | — | EP | disclosed |
| US-9598370-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3026044-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20160009648-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | disclosed |
| EP-2892892-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR!THE TREATMENT OF CANCER | Janssen Pharmaceutica N.V. (BE) | 2015-07-15 | — | — | EP | disclosed |
| US-20150119425-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT COMPANY, LLC (PR) | 2015-04-30 | — | — | US | disclosed |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, NV (BE) | 2015-04-09 | — | — | US | disclosed |
| US-8940773-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8722895-B2 | Prolyl hydroxylase inhibitors and method of use | AKEBIA THERAPEUTICS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| WO-2014039769-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR|THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-13 | — | — | WO | disclosed |
| US-20140057892-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140045899-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8598210-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130245076-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHOD OF USE | AKEBIA THERAPEUTICS INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130203816-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-8343952-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8323671-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8273741-B2 | Imidazo-pyridazinyl compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8044049-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8034812-B2 | Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-11 | — | — | US | disclosed |
| EP-2327696-A1 | Prolyl hydroxylase inhibitors and methods of use | Warner Chilcott Company, LLC (PR) | 2011-06-01 | — | — | EP | disclosed |
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100273788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-28 | — | — | US | disclosed |
| EP-2044005-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT CO LLC (PR) | 2010-10-20 | — | — | EP | disclosed |
| US-7811595-B2 | such as {[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester; for controlling Peripheral Vascular Disease, Coronary Artery Disease, heart failure, ischemia, and anemia | WARNER CHILCOTT COMPANY, LLC (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | disclosed |
| US-20090306374-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| CN-101506149-A | Prolyl hydroxylase inhibitors and methods of use | PROCTER & GAMBLE (US) | 2009-08-12 | — | — | CN | disclosed |
| EP-1812424-A4 | KINASE INHIBITORS | MIIKANA THERAPEUTICS INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2049541-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008016192-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
| EP-1812424-A2 | KINASE INHIBITORS | Miikana Therapeutics, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006055831-A2 | KINASE INHIBITORS | MIIKANA THERAPEUTICS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1635824-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | Novartis AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005000298-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | disclosed |
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | disclosed |
| CN-1343206-A | Cyclocompound | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-04-03 | — | — | CN | disclosed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
| EP-0192111-B1 | ISO-UREAS, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS HERBICIDES | BASF Aktiengesellschaft (DE) | 1990-05-16 | — | — | EP | disclosed |
| US-4692187-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1987-09-08 | — | — | US | disclosed |
| EP-0192111-A1 | Iso-ureas, processes for their production and their use as herbicides | BASF Aktiengesellschaft (DE) | 1986-08-27 | — | — | EP | disclosed |
| EP-0192111-A1 | Iso-ureas, processes for their production and their use as herbicides | BASF Aktiengesellschaft (DE) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (27 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | GAA 3805/4885MEN1 2551/4885KMT2A 1144/4885 |
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | GAA 139/4885MEN1 4614/4885KMT2A 967/4885 |
| US-11883386-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | GAA 139/4885MEN1 4614/4885KMT2A 967/4885 |
| US-20190192494-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 139/4885MEN1 4614/4885KMT2A 967/4885 |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | GAA 2501/4885MEN1 1696/4885KMT2A 4293/4885 |
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 139/4885MEN1 4614/4885KMT2A 967/4885 |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | GAA 3805/4885MEN1 2551/4885KMT2A 1144/4885 |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 139/4885MEN1 4614/4885KMT2A 967/4885 |
| US-20100004298-A1 | P-38 INHIBITORS | MAPK8, MAPK1, MAP3K8 | GAA 2702/4885MEN1 4323/4885KMT2A 3683/4885 |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | FASN, PLIN1, FABP1 | GAA 2501/4885MEN1 1696/4885KMT2A 4293/4885 |
| US-20180327401-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | GAA 2501/4885MEN1 1696/4885KMT2A 4293/4885 |
| US-20040254236-A1 | P-38 inhibitors | MAPK8, MAP3K8, MAPK1 | GAA 2596/4885MEN1 4051/4885KMT2A 3842/4885 |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | GAA 110/4885MEN1 2780/4885KMT2A 2541/4885 |
| US-20160009648-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 139/4885MEN1 4614/4885KMT2A 967/4885 |
| US-20140057892-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 148/4885MEN1 4618/4885KMT2A 1008/4885 |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 139/4885MEN1 4614/4885KMT2A 967/4885 |
| US-20130245076-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHOD OF USE | HIF1AN, EGLN3, HIF1A | GAA 129/4885MEN1 4620/4885KMT2A 965/4885 |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | GAA 139/4885MEN1 4614/4885KMT2A 967/4885 |
| US-20130203816-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 139/4885MEN1 4614/4885KMT2A 967/4885 |
| US-10729681-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | GAA 139/4885MEN1 4614/4885KMT2A 967/4885 |
| US-20090306374-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | GAA 3805/4885MEN1 2551/4885KMT2A 1144/4885 |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | GAA 2501/4885MEN1 1696/4885KMT2A 4293/4885 |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 139/4885MEN1 4614/4885KMT2A 967/4885 |
| US-20140045899-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 139/4885MEN1 4614/4885KMT2A 967/4885 |
| US-20150119425-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 139/4885MEN1 4614/4885KMT2A 967/4885 |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | GAA 3862/4885MEN1 2426/4885KMT2A 1189/4885 |
| US-20170189387-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 139/4885MEN1 4614/4885KMT2A 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.